Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Histologic or cytologic diagnosis of stage IIIB/IV NSCLC
ECOG PS: 0,1
Unidimensional or bi-dimensional measurable disease
Receive prior treatment including first-line platinum-based chemotherapy, standard second-line chemotherapy and 1 EGF/EGFR inhibitor
Evidence of disease progression
Life expectancy \>12 weeks
Neutrophils \> 1.5 109/l, Platelets \> 100 109/l, Hemoglobin \> 9g/dl, Total bilirubin \< 1.5 UNL, AST (SGOT) and ALT (SGPT) \< 2.5 UNL, Alkaline phosphatases \< 5 UNL, Creatinine \< 1 UNL

Pre-existing hemoptysis of a severity \> grade 3 by NCI CTCAE criteria within 4 weeks prior to study entry
Uncontrolled hypertension
CHF, angina or arrhythmias
LVEF \< 1 UNL
Existing a second malignancy within 5 years
Infected with HIV

Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen